Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	5.99	1.19	4.6
Cash & Short-Term Investments	5.99	1.19	4.6
Cash Growth	404.72%	-74.17%	-
Other Current Assets	0.65	1.06	0.38
Total Current Assets	6.64	2.25	4.98
Net Property, Plant & Equipment	0.44	0.56	0.25
Other Long-Term Assets	0.14	0.05	0.03
Total Assets	7.22	2.86	5.26
Accounts Payable	1.7	1.72	0.32
Accrued Expenses	0.88	0.64	1.57
Short-Term Debt	-	1	-
Current Portion of Leases	0.18	0.16	0.11
Other Current Liabilities	-	0	0.2
Total Current Liabilities	2.76	3.52	2.2
Long-Term Debt	1.57	2.96	-
Long-Term Leases	0.29	0.37	0.06
Total Long-Term Liabilities	1.85	3.33	0.06
Total Liabilities	4.61	6.85	2.26
Common Stock	0.04	0	-
Additional Paid-in Capital	57.73	39.26	11.34
Retained Earnings	-55.17	-43.25	-26.81
Shareholders' Equity	2.6	-3.99	-15.48
Total Liabilities & Equity	7.22	2.86	5.26
Total Debt	2.04	4.49	0.17
Net Cash (Debt)	3.96	-3.3	4.42
Net Cash Per Share	2.98	-79.36	593.95
Book Value	2.6	-3.99	-15.48
Book Value Per Share	1.96	-95.81	-2077.75
Tangible Book Value	2.6	-3.99	-15.48
Tangible Book Value Per Share	1.96	-95.81	-2077.75

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q